Proteinase Activated Receptor 2 - Pipeline Review, H2 2019
Proteinase Activated Receptor 2 - Pipeline Review, H2 2019
SUMMARY
Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Protease activated receptor 2 (PAR2) also known as coagulation factor II (thrombin) receptor-like 1 (F2RL1) is a protein encoded by the F2RL1 gene. PARs (protease-activated receptors) are G-protein-coupled receptors for proteases from the circulation, inflammatory cells and epithelial tissues. PAR2 plays an important role in inflammation and pain. Pancreatic (trypsin I and II) and extrapancreatic (trypsin IV) trypsins, mast cell tryptase and coagulation factors VIIa and Xa cleave and activate PAR 2.
Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Immunology, Dermatology, Respiratory, Cardiovascular, Genito Urinary System And Sex Hormones, Metabolic Disorders and Oncology which include indications Atopic Dermatitis (Atopic Eczema), Inflammation, Non-Alcoholic Steatohepatitis (NASH), Celiac Disease, Idiopathic Pulmonary Fibrosis, Inflammatory Bowel Disease, Kidney Fibrosis, Obesity, Psoriasis, Pulmonary Fibrosis, Pulmonary Hypertension and Type 2 Diabetes.
The latest report Proteinase Activated Receptor 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Protease activated receptor 2 (PAR2) also known as coagulation factor II (thrombin) receptor-like 1 (F2RL1) is a protein encoded by the F2RL1 gene. PARs (protease-activated receptors) are G-protein-coupled receptors for proteases from the circulation, inflammatory cells and epithelial tissues. PAR2 plays an important role in inflammation and pain. Pancreatic (trypsin I and II) and extrapancreatic (trypsin IV) trypsins, mast cell tryptase and coagulation factors VIIa and Xa cleave and activate PAR 2.
Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Immunology, Dermatology, Respiratory, Cardiovascular, Genito Urinary System And Sex Hormones, Metabolic Disorders and Oncology which include indications Atopic Dermatitis (Atopic Eczema), Inflammation, Non-Alcoholic Steatohepatitis (NASH), Celiac Disease, Idiopathic Pulmonary Fibrosis, Inflammatory Bowel Disease, Kidney Fibrosis, Obesity, Psoriasis, Pulmonary Fibrosis, Pulmonary Hypertension and Type 2 Diabetes.
The latest report Proteinase Activated Receptor 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1)
- The report reviews Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Overview
Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Companies Involved in Therapeutics Development
Hadasit Medical Research Services and Development Ltd
Innovate Biopharmacueticals Inc
Oasis Pharmaceuticals LLC
PeptiDream Inc
Sosei Heptares
Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Drug Profiles
GB-88 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larazotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize PAR2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize PAR-2 for Atopic Dermatitis and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-2pal18S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Antagonize PAR-1 and PAR-2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PZ-235 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize PAR2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Dormant Products
Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Product Development Milestones
Featured News & Press Releases
Aug 13, 2019: Innovate Biopharmaceuticals announces first patient dosed in the first phase 3 clinical trial for patients with celiac disease
Jul 15, 2019: Innovate Biopharmaceuticals announces corporate update and expected date for second quarter earnings release
Jun 24, 2019: Innovate Biopharmaceuticals expands its management team with the addition of Ed Sitar as Its Chief Financial Officer
Jun 10, 2019: Innovate Biopharmaceuticals announces the start of the first phase 3 clinical trial in Celiac Disease
May 20, 2019: Innovate Biopharmaceuticals announces presentation of three posters focusing on the molecular biology and pharmacology of Larazotide at the 2019 Digestive Disease Week Conference in San Diego
Apr 29, 2019: Innovate Biopharmaceuticals shows Larazotide is the first drug, with its novel mechanism of action of re-normalizing the intestinal barrier, to demonstrate improvements in validated NASH biomarkers and endpoints in synergy with obeticholic acid, an FXR ag
Apr 11, 2019: Innovate Biopharmaceuticals presents oral poster at European Association for the Study of the Liver (EASL) demonstrating positive effect of larazotide on reduced intestinal permeability in a NASH preclinical study
Apr 02, 2019: Innovate Biopharmaceuticals to announce first quarter 2019 financial results and to provide operational progress updates on April 29, 2019
Mar 19, 2019: Innovate Biopharmaceuticals reports financing to initiate the first phase 3 clinical trial in celiac disease
Feb 25, 2019: Innovate Biopharmaceuticals announces acceptance of three abstracts focusing on the molecular biology and pharmacology of Larazotide for the 2019 Digestive Disease Week Conference
Dec 17, 2018: Innovate Biopharmaceuticals plans to commence the first ever phase 3 registration trial in celiac disease in 1H 2019 and announce top-line NASH data with drug combinations by EASL 2019
Nov 12, 2018: Sanyal Biotechnology and Innovate Biopharmaceuticals present data at AASLD validating a proprietary Leaky Gut assay demonstrating reduced intestinal permeability with Larazotide Acetate treatment in a NASH preclinical study
Oct 29, 2018: Innovate Biopharmaceuticals announces positive effect of Larazotide Acetate on reducing intestinal permeability in a NASH preclinical study
May 17, 2018: Celiac Disease KOL and Management Meetings around the Digestive Disease Week (DDW) conference on Monday, June 4, 2018, in Washington, D.C.
May 09, 2018: Innovate Biopharmaceuticals Announces Acceptance of Two Abstracts for the Digestive Disease Week 2018 Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Overview
Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Companies Involved in Therapeutics Development
Hadasit Medical Research Services and Development Ltd
Innovate Biopharmacueticals Inc
Oasis Pharmaceuticals LLC
PeptiDream Inc
Sosei Heptares
Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Drug Profiles
GB-88 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larazotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize PAR2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize PAR-2 for Atopic Dermatitis and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-2pal18S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Antagonize PAR-1 and PAR-2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PZ-235 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize PAR2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Dormant Products
Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Product Development Milestones
Featured News & Press Releases
Aug 13, 2019: Innovate Biopharmaceuticals announces first patient dosed in the first phase 3 clinical trial for patients with celiac disease
Jul 15, 2019: Innovate Biopharmaceuticals announces corporate update and expected date for second quarter earnings release
Jun 24, 2019: Innovate Biopharmaceuticals expands its management team with the addition of Ed Sitar as Its Chief Financial Officer
Jun 10, 2019: Innovate Biopharmaceuticals announces the start of the first phase 3 clinical trial in Celiac Disease
May 20, 2019: Innovate Biopharmaceuticals announces presentation of three posters focusing on the molecular biology and pharmacology of Larazotide at the 2019 Digestive Disease Week Conference in San Diego
Apr 29, 2019: Innovate Biopharmaceuticals shows Larazotide is the first drug, with its novel mechanism of action of re-normalizing the intestinal barrier, to demonstrate improvements in validated NASH biomarkers and endpoints in synergy with obeticholic acid, an FXR ag
Apr 11, 2019: Innovate Biopharmaceuticals presents oral poster at European Association for the Study of the Liver (EASL) demonstrating positive effect of larazotide on reduced intestinal permeability in a NASH preclinical study
Apr 02, 2019: Innovate Biopharmaceuticals to announce first quarter 2019 financial results and to provide operational progress updates on April 29, 2019
Mar 19, 2019: Innovate Biopharmaceuticals reports financing to initiate the first phase 3 clinical trial in celiac disease
Feb 25, 2019: Innovate Biopharmaceuticals announces acceptance of three abstracts focusing on the molecular biology and pharmacology of Larazotide for the 2019 Digestive Disease Week Conference
Dec 17, 2018: Innovate Biopharmaceuticals plans to commence the first ever phase 3 registration trial in celiac disease in 1H 2019 and announce top-line NASH data with drug combinations by EASL 2019
Nov 12, 2018: Sanyal Biotechnology and Innovate Biopharmaceuticals present data at AASLD validating a proprietary Leaky Gut assay demonstrating reduced intestinal permeability with Larazotide Acetate treatment in a NASH preclinical study
Oct 29, 2018: Innovate Biopharmaceuticals announces positive effect of Larazotide Acetate on reducing intestinal permeability in a NASH preclinical study
May 17, 2018: Celiac Disease KOL and Management Meetings around the Digestive Disease Week (DDW) conference on Monday, June 4, 2018, in Washington, D.C.
May 09, 2018: Innovate Biopharmaceuticals Announces Acceptance of Two Abstracts for the Digestive Disease Week 2018 Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Hadasit Medical Research Services and Development Ltd, H2 2019
Pipeline by Innovate Biopharmacueticals Inc, H2 2019
Pipeline by Oasis Pharmaceuticals LLC, H2 2019
Pipeline by PeptiDream Inc, H2 2019
Pipeline by Sosei Heptares, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Hadasit Medical Research Services and Development Ltd, H2 2019
Pipeline by Innovate Biopharmacueticals Inc, H2 2019
Pipeline by Oasis Pharmaceuticals LLC, H2 2019
Pipeline by PeptiDream Inc, H2 2019
Pipeline by Sosei Heptares, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Hadasit Medical Research Services and Development Ltd
Innovate Biopharmacueticals Inc
Oasis Pharmaceuticals LLC
PeptiDream Inc
Sosei Heptares
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Hadasit Medical Research Services and Development Ltd
Innovate Biopharmacueticals Inc
Oasis Pharmaceuticals LLC
PeptiDream Inc
Sosei Heptares
